Rafael Holdings Inc (RFL)

$1.35 -0.01 (-0.74%)
Market Cap 47.37M
Revenue (ttm) 640,000.00
Net Income (ttm) -34.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,376.56%
Debt to Equity Ratio 0.01
Volume 42,400
Avg Vol 127,930
Day's Range N/A - N/A
Shares Out 35.09M
Stochastic %K 36%
Beta 0.85
Analysts Strong Buy
Price Target N/A

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylat...

Industry: Real Estate Services
Sector: Real Estate
Phone: 212 658 1450
Address:
520 Broad Street, Newark, United States
JB20901
JB20901 Oct. 24 at 3:32 PM
$RFL looks like a nice spot
0 · Reply
Moksi
Moksi Oct. 24 at 3:41 AM
$RFL 200
1 · Reply
Pabah23
Pabah23 Oct. 22 at 11:09 PM
$RFL We held up great today what a champ 🤣🤣 My grandkids may enjoy the move up one day!! Maybe
0 · Reply
solistocks
solistocks Oct. 20 at 5:46 PM
$RFL just saw this on Facebook.
1 · Reply
RemitTekram
RemitTekram Oct. 15 at 7:41 PM
$RFL
0 · Reply
Lehameri
Lehameri Oct. 15 at 7:13 PM
$RFL man first half really feels far away. How disconcerting.
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Oct. 15 at 2:09 PM
$RFL 1st half of 2026!???!?? My goodness. They have $62M. Didn’t take the time to look at burn rate but my guess is 10-12M. We won’t make it to April… another dilution coming… can’t we just catch a break here…
0 · Reply
MK2020
MK2020 Oct. 15 at 11:31 AM
$RFL they dont say something about the alzheimer study ... thats sad, but i can understand, that they have to focus on NPC.
0 · Reply
MK2020
MK2020 Oct. 15 at 11:30 AM
$RFL
0 · Reply
sg44
sg44 Oct. 14 at 6:57 PM
$RFL https://d2ghdaxqb194v2.cloudfront.net/2323/198444.pdf
0 · Reply
Latest News on RFL
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Sep 16, 2025, 8:00 AM EDT - 5 weeks ago

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 11, 2025, 7:00 AM EDT - 4 months ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Jun 4, 2025, 4:01 PM EDT - 5 months ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 20, 2025, 4:01 PM EDT - 5 months ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 6 months ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 6 months ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Apr 24, 2025, 4:15 PM EDT - 6 months ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 26, 2025, 6:50 AM EDT - 7 months ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Mar 13, 2025, 5:50 PM EDT - 8 months ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Feb 20, 2025, 4:35 PM EST - 8 months ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Dec 11, 2024, 7:00 AM EST - 11 months ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Nov 6, 2024, 7:14 PM EST - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 13, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

May 2, 2023, 8:12 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Mar 14, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jul 6, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 2:14 PM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 16, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 14, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

May 24, 2022, 11:04 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 17, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 11, 2022, 4:00 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 2:26 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

Jan 21, 2022, 7:00 AM EST - 4 years ago

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 18, 2022, 8:30 AM EST - 4 years ago

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Jan 6, 2022, 8:30 AM EST - 4 years ago

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

JB20901
JB20901 Oct. 24 at 3:32 PM
$RFL looks like a nice spot
0 · Reply
Moksi
Moksi Oct. 24 at 3:41 AM
$RFL 200
1 · Reply
Pabah23
Pabah23 Oct. 22 at 11:09 PM
$RFL We held up great today what a champ 🤣🤣 My grandkids may enjoy the move up one day!! Maybe
0 · Reply
solistocks
solistocks Oct. 20 at 5:46 PM
$RFL just saw this on Facebook.
1 · Reply
RemitTekram
RemitTekram Oct. 15 at 7:41 PM
$RFL
0 · Reply
Lehameri
Lehameri Oct. 15 at 7:13 PM
$RFL man first half really feels far away. How disconcerting.
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Oct. 15 at 2:09 PM
$RFL 1st half of 2026!???!?? My goodness. They have $62M. Didn’t take the time to look at burn rate but my guess is 10-12M. We won’t make it to April… another dilution coming… can’t we just catch a break here…
0 · Reply
MK2020
MK2020 Oct. 15 at 11:31 AM
$RFL they dont say something about the alzheimer study ... thats sad, but i can understand, that they have to focus on NPC.
0 · Reply
MK2020
MK2020 Oct. 15 at 11:30 AM
$RFL
0 · Reply
sg44
sg44 Oct. 14 at 6:57 PM
$RFL https://d2ghdaxqb194v2.cloudfront.net/2323/198444.pdf
0 · Reply
Biotechnicity
Biotechnicity Oct. 12 at 11:59 PM
$RFL who buys this gem anyway? So prom…
0 · Reply
GoldmanSlaps
GoldmanSlaps Oct. 9 at 1:31 AM
$RFL hot dam I just looked at my average
0 · Reply
northmark1
northmark1 Oct. 8 at 5:35 PM
$RFL People are Bailing out! Jumping Ship! This thing is Going Down Fast! No News! No Progress or Results from Testing Drugs are a Bust. Its all a Pipe Dream! See you in the OTC at .49 a share..
2 · Reply
Love_To_Learn
Love_To_Learn Oct. 7 at 11:34 AM
$RFL using 1.52 super filler for markets belongs to u $SNGX also me off 1.52 1.56 * sngx !
0 · Reply
Biotechnicity
Biotechnicity Oct. 7 at 12:06 AM
$RFL Zevra hired two new, unnamed employees. Their stock is ascending as if a buyout is near. Can both things be true? Hiring for the future but gone tomorrow. Inbetweenish
1 · Reply
Love_To_Learn
Love_To_Learn Oct. 6 at 5:46 PM
$RFL will b using your super filler for markets and a relative to u half breed 1.52 filler and 1.56* post above 2pt ! another stock coming
1 · Reply
Biotechnicity
Biotechnicity Oct. 6 at 3:59 PM
$RFL Rediculish
0 · Reply
RemitTekram
RemitTekram Oct. 6 at 1:45 PM
$RFL Back to the buy zone!
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Oct. 2 at 6:11 PM
$RFL last one from me. I just grabbed a few more crumbs to bring my DCA down to $6.90. With over 10k shares, let’s get that news and put some money back in my pocket!?!
2 · Reply
CaseOfTheYips1
CaseOfTheYips1 Oct. 2 at 5:52 PM
$RFL for those wondering about next quarterly, RFL is usually late on the full year. October 30th and November 6th for the past 2 years respectively. If nothing else, that’s our next update…
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Oct. 1 at 9:08 PM
$RFL October is here… when is our time? Btw, I Fing hate SAVA…
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 30 at 10:51 AM
$RFL $JAGX modifying the old reverse park job 1.09-1.12 for entire stock market for you and what is coming for u later and your updates
0 · Reply